GPN Vaccines

Executive Summary

GPN Vaccines is an Australian clinical-stage biotechnology company developing a universal pneumococcal vaccine based on a proprietary gamma-irradiated whole-cell bacterial platform. Unlike traditional vaccines that target serotype-specific capsular polysaccharides, GPN's vaccine leverages conserved, capsule-independent proteins to provide broad coverage against all pneumococcal serotypes without requiring adjuvants. The approach aims to address the limitations of current pneumococcal vaccines, which offer incomplete serotype coverage and can lead to serotype replacement. With Phase 1 clinical trials underway, the company is evaluating safety and immunogenicity in healthy adults and children, positioning itself to address a significant unmet need in global infectious disease prevention. Founded in 2020 and based in Adelaide, GPN Vaccines has grown to over 200 employees and represents an innovative approach in vaccinology with potential for both pediatric and adult populations.

Upcoming Catalysts (preview)

• Q1 2026Phase 1 interim safety and immunogenicity data readout70% success
• Q3 2025Completion of Phase 1 trial enrollment90% success
• Q4 2026Initiation of Phase 2 trial planning60% success